rexroad

CMS now requires hospitals to publish machine-readable price files under the Hospital Price Transparency Rule (effective 2021, enforcement added 2022). Compliance rates are technically high. The problem is the files run tens of thousands of line items in inconsistent formats, negotiated rates vary by insurance plan, and chargemaster list prices bear no predictable relationship to what any patient actually pays.

RAND's Round 5.1 study analyzed actual paid claims rather than posted prices and found commercial insurers paid 254% of Medicare rates for identical procedures at the same hospitals. The transparency is on paper. The opacity is structural: a price list is only useful if a purchaser can act on it, and the moment of care is not when most patients can comparison shop. Which is why reference pricing works at the employer level (purchaser can act in advance on a population basis) but published hospital price lists have not moved the market.

Agreed on the diagnosis: the inpatient hospital market does not function as a competitive market. Patients arriving by ambulance do not shop on price. Insurance insulates consumers from marginal cost. Regulatory and capital barriers prevent new entrants. The HCRIS FY2023 data for 3,193 hospitals shows what this produces: a 2.6x median markup to actual cost, with the highest-markup hospitals rarely losing patients to lower-cost alternatives nearby.

Your examples of what works are instructive. Generic OTC, needles, blood panels all share the same conditions: price-visible, consumer-controlled, no third-party payment insulation. The RAND hospital data shows the identical procedure (hip replacement) costing $29K commercially in the US versus $14.7K in Germany and $8.7K in Spain. Same implant, same surgeon training requirements. The patient's insurance status varies; the procedure does not.

Montana's commercial reference pricing is not deregulation, but it creates the price-visibility function you are describing: a known floor price that makes it possible for a purchaser to act on price information. Employers have adopted it nationally with documented savings.

For-profit structure is part of the problem but not all of it. Issue 3 analyzed 3,193 hospitals using CMS HCRIS FY2023 cost reports. For-profit hospitals do have the highest cost-to-charge markups: 4.11x median. But nonprofits are 2.46x, and nonprofits hold 75.5% of total national hospital supply spend. The ownership form does not reliably determine pricing behavior when market conditions are the same: opaque prices, patients who cannot shop, no reference price to anchor negotiation.

Maryland has had all-payer hospital rate-setting since 1977 with a largely nonprofit hospital sector. It produces significantly better cost control than the national average. The structural fix for hospital pricing (commercial reference pricing at 200% of Medicare) works regardless of tax status because it creates a known floor price. That is what the RAND data and the Montana Medicaid experience both show. The mechanism matters more than the ownership form.

The direction is right. Total US healthcare spending is $4.87T for 335M people ($14,570/capita, CMS NHE 2023). Japan's per-capita is $5,790, with the highest life expectancy in the world and lowest infant mortality in the OECD. The annual national gap is approximately $3T.

The series is not arguing for a specific coverage structure. It is documenting where the excess goes, mechanism by mechanism. Four issues in, $128.6B is accounted for conservatively: drug pricing, hospital commercial markups, PBM extraction. Each mechanism has a defensible, operationally precedented fix that does not require redesigning the entire system. Montana Medicaid adopted commercial reference pricing at 200% of Medicare and measured no quality deterioration. The FTC documented PBM specialty drug markups and three states have already enacted clawback restrictions. None of that required universal healthcare.